Navigation Links
Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027
Date:10/25/2011

SAN DIEGO, Oct. 25, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants.

The top priority of Conatus is patient safety, and the Company has made the decision to halt this study.  Conatus is conducting a thorough review of the available data to assess any future development of the compound.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can be caused by many different types of injuries. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer.  Conatus acquired the Idun subsidiary from Pfizer in 2010.  For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)
2. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
3. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
4. Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
5. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
6. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
7. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
8. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... Professor of Engineering at the University of Delaware, ... problems in energy engineering, environmental sustainability and electronics. ... porous rock with a well-defined, crystalline structure. At ... precisely decided that zeolites can separate molecules with ... angstrom (one-tenth of a nanometer), making them useful ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2
... JOSE, Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... the minimally invasive treatment of peripheral vascular disease,announced today ... the,fourth quarter ended December 31, 2007, after the close ... its regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 ...
... soda and hot chocolate present risk, OAKLAND, ... caffeine,during pregnancy -- whether from coffee, tea, caffeinated ... of miscarriage, according a new study,by the Kaiser ... first time, pregnancy-related symptoms of nausea, vomiting and ...
... The San Diego Consortium for,Regenerative Medicine (SDCRM) today ... three of four categories from the California Institute ... Major Facilities Grant,Application., SDCRM,s application, which was ... research and discovery, 95 for preclinical research, 94 ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 2SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 3
(Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva ... from cardiac devices, has cut emergency room wait times ... San Diego (UCSD) Medical Center, according to a recent ... UCSD Emergency Departments are using the suite to access ... pacemakers or defibrillators. "Using Geneva,s technology platform ...
(Date:7/24/2014)... over a 35 year period in which the human ... humans on declining animal numbers. This decline matters because ... crustaceans, slugs and worms bring to our day-to-day lives, ... nutrient cycling, water filtration and human health. , The ... UCL, Stanford and UCSB, focused on the demise of ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... devastated the Gulf of Mexico ecologically and economically. However, a ... the true impact of the disaster on wildlife may be ... the number of recovered animal carcasses will not give a ... believed. "The Deepwater oil spill was the largest in ...
... at Michigan State University has revealed a potential new way ... Howe, biochemistry and molecular biology professor, cites that this defense ... race between plants and herbivores. Howe, in the current ... Sciences, offers insights to understanding the chemical weaponry of ...
... being able to capture the "evanescent" light waves that ... far enough to be "seen" by a conventional lens. ... depending upon the form of light they capture, ... been made from elaborate artificial constructs known as metamaterials. ...
Cached Biology News:Whale and dolphin death toll during Deepwater disaster may have been greatly underestimated 2Whale and dolphin death toll during Deepwater disaster may have been greatly underestimated 3The way to (kill) a bug's heart is through its stomach 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 2Berkeley Lab researchers make first perovskite-based superlens for the infrared 3Berkeley Lab researchers make first perovskite-based superlens for the infrared 4Berkeley Lab researchers make first perovskite-based superlens for the infrared 5
BAI-1 (T-20)...
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
... Immunogen: Synthetic peptide derived from the ... rat ZO-1. Specificity: Specific for the ... Reactivity: Human Dog Rat Mouse (positive ... frozen mouse liver heart blood vessel and ...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
Biology Products: